The global narcolepsy therapeutics market is currently in a state of rapid development and dynamic growth, which presents numerous prospects for life science businesses. In order to enhance the quality of life for those who have narcolepsy, businesses that are already working on narcolepsy medicines are attempting to sell cutting-edge treatment solutions. Companies in the worldwide narcolepsy therapeutics market are now putting more of an emphasis on individualised and disease-specific treatment choices. Major firms are also making significant investments in research and development for their individual therapeutic products, like Jazz Pharmaceuticals PLC, Takeda Pharmaceuticals Co. Ltd, and Bioproject Pharma.

The global  narcolepsy therapeutics market  is projected to reach $4,912.3 million by 2032 from $915.2 million in 2021 at a CAGR of 15.93% during the forecast period 2022-2032. This The market is driven by certain factors, such as low satisfaction with available therapies, robust pipeline products, rising uptake of narcolepsy awareness programs, and improving diagnosis.

Impact

Albeit narcolepsy is an orphan disorder with only about 3 million people globally, the existing management of narcolepsy propounds the area as investigational for drug research and development. Currently, all available therapies are symptom-centric and do not cure the condition. In about 50% of people, onset disorder often occurs prior to age 25 with a delayed diagnosis, especially in adolescents. Insubstantial abilities of existing therapies to cover a complete range of symptoms and insignificant improvement in the quality of life of people with narcolepsy have led to the emergence of several innovative therapies in recent years. The market witnessed approximately 39 regulatory and legal developments during the time period between January 2019 and May 2022.

In addition, the disorder profoundly increases the psychosocial burden on people with narcolepsy. Associated high treatment costs and dwindled work productivity with reduced income levels are some of the key factors adding to the psychosocial burden for people living with narcolepsy. Most companies are focusing on expanding their product portfolio with the launch of best-in-class distinctive novel therapeutics and trying to address the limitations and challenges with available therapies in an effort to increase their global footprint alongside

Market segmentation

Segmentation 1: by indication
• Type 1 narcolepsy
• Type 2 narcolepsy 
• Secondary narcolepsy

Due to recent research and development in type 1 narcolepsy, significant therapies with novel mechanisms of action, reduced dosage, and better efficacy are emerging. Therefore, the segment is dominated by type 1 narcolepsy, which held a share of 69.60% in 2021.

Segmentation 2: by product
• commercialized products
• pipeline products

In 2021, the global narcolepsy therapeutics market (by product) is dominated by commercialized products with 100% market share.

Segmentation 3: by Therapeutic Type
• Central Nervous System Stimulant
• Norepinephrine Reuptake Inhibitor 
• Histamine-3 (H3) Receptor Antagonist/Inverse Agonist

The global narcolepsy therapeutics market (by therapeutics) is currently dominated by central nervous system stimulants, with a value of $535.3 million, as of 2021.

Segmentation 4: by Country
• US
• Germany
• Italy
• France
• UK
• Spain
• Japan

In 2021, the US accounted for a share of 93.48% of the global narcolepsy therapeutics market. The segment is expected to reach $4,327.7 million in 2032 from $855.5 million in 2021 at a CAGR of 15.24% during the forecast period 2022-2032.

Global Narcolepsy Therapeutics Market Dynamics

Recent Developments in the Global Narcolepsy Therapeutics Market

• On March 28, 2022, Jazz Pharmaceuticals PLC divested Sunosi. Axsome Therapeutics, Inc. intends to expand its presence in neuroscience by acquiring Sunosi (solriamfetol) from Jazz Pharmaceuticals PLC.
• On August 31, 2021, Health Canada approved Jazz Pharmaceutical's Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy.
• On August 10, 2021, Harmony Biosciences LLC's successful track record of Wakix motivated Blackstone to enter a strategic financing collaboration, where the company agreed to invest up to $330.0 million of financing and growth capital in Harmony Biosciences LLC.
• On September 16, 2021, Axsome Therapeutics, Inc. announced the enrollment of the first patient in the new phase 3 clinical trial SYMPHONY (a study evaluating a mechanistic approach to treating narcolepsy) of AXS-12 in narcoleptic patients.

Analyst’s Perspective

According to Sara Virmani, Senior Research Analyst, BIS Research, “The global narcolepsy therapeutics market is in a dynamic stage. Low satisfaction with available therapies, improved recently rising marketed therapies, robust pipeline products, uptake of narcolepsy awareness programs, and improving diagnosis are contributing to significant growth of the market during the period.. The continued substantial investments by healthcare companies and government authorities to meet demand and the growing adoption of emerging trends are the major factors propelling the growth of the global narcolepsy therapeutics market.”

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Jazz Pharmaceuticals PLC
Harmony Bioscience, LLC
Axsome Therapeutics, Inc.
Avadel Pharmaceuticals PLC
Takeda Pharmaceutical Co Ltd
Sumitomo Pharma Co Ltd
Suven Life Sciences Limited
NLS Pharmaceutics AG
Balance Therapeutics

View the report   on the   Global Narcolepsy Therapeutics Market